<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01286376</url>
  </required_header>
  <id_info>
    <org_study_id>COSI</org_study_id>
    <nct_id>NCT01286376</nct_id>
  </id_info>
  <brief_title>Evaluating the Effectiveness of LACTOFOS in Constipated Patients</brief_title>
  <acronym>COSI</acronym>
  <official_title>Randomized, Double Blind, Comparative LACTOFOS With Placebo in Constipation Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sao Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ganep Human Nutrition</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Sao Paulo</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Determine the effectiveness of symbiotic LACTOFOS containing FOS and probiotics against&#xD;
      placebo in patients with a diagnosis of constipation, comparing the average number of weekly&#xD;
      evacuations in 2 (two) groups for 30 days.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A prospective, randomized, double blind, parallel group. Consist of a period of 30 days of&#xD;
      treatment with placebo or with LACTOFOS.Will study 120 patients were female with a diagnosis&#xD;
      of constipation according to Rome III criteria for at least 3 (three) months.&#xD;
&#xD;
      The experimental group (N = 60)will receive LACTOFOS 12g/day in two doses of 6 g. The control&#xD;
      group (N = 60)will receive a placebo (maltodextrin) from 12g/day in two shots of 6 g.&#xD;
&#xD;
      Subsequently, the patients will be classified according to the study of AGACHAN, which&#xD;
      determined a score based on the main complaints of patients. The symptoms that included&#xD;
      evaluation for the total score were stool frequency, difficulty / straining, pain at&#xD;
      defecation, feeling of incomplete evacuation, abdominal pain, time taken to initiate the&#xD;
      evacuation, type of assistance for evacuation, failed attempts / day and duration of&#xD;
      constipation. The intensity of each symptom varied within the range of 0 to 4, with the&#xD;
      exception of the item type of assistance for evacuation, which ranged from 0 to 2.&#xD;
&#xD;
      Constipation is classified as mild when the total sum of values (scores) vary from 00 to 10,&#xD;
      as moderate when the sum of the values obtained vary from 11 to 20 and severe when the final&#xD;
      sum range from 21 to 30.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2010</start_date>
  <completion_date type="Anticipated">August 2011</completion_date>
  <primary_completion_date type="Anticipated">March 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of stool - Chart</measure>
    <time_frame>30 days</time_frame>
    <description>30 days taking 2 times per day. At morning and night</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Constipation</condition>
  <arm_group>
    <arm_group_label>symbiotic</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Symbiotic Lactofos</intervention_name>
    <description>Lactobacillus Paracasei Lactobacillus Rhamnosus Lactobacillus Acidophilus Bifidobacterium lactis 12g/day</description>
    <arm_group_label>symbiotic</arm_group_label>
    <other_name>prebiotcs</other_name>
    <other_name>probiotcs</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Maltodextrin</intervention_name>
    <description>Maltodextrin</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Females aged 18-75 years&#xD;
&#xD;
          2. A diagnosis of constipation defined by Rome III criteria&#xD;
&#xD;
          3. Ability to good communication with the investigator and agreeing to requests from the&#xD;
             entire study&#xD;
&#xD;
          4. Patients must sign a formal consent to participate&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Constipation drug source&#xD;
&#xD;
          2. History or evidence of organic disease of the gastrointestinal tract such as tumors,&#xD;
             inflammatory bowel disease, etc.. proven by radiological or endoscopic examination of&#xD;
             the bowel (five years before and after onset of symptoms). If the investigator has&#xD;
             doubts should request the necessary procedures, such as sigmoidoscopy, colonoscopy or&#xD;
             edema bariatric to exclude organic disease&#xD;
&#xD;
          3. History of laxative use which in the opinion of the investigator is consistent with&#xD;
             severe laxative dependence&#xD;
&#xD;
          4. Current History recent (12 months) of significant abuse of alcohol or drugs&#xD;
&#xD;
          5. History of malignancy in 5 (five) previous years (except basal cell carcinoma treated&#xD;
             well or cervical carcinoma in situ)&#xD;
&#xD;
          6. Known history of cardiovascular control inappropriate and / or significant&#xD;
             respiratory, renal, hepatic, gastrointestinal, hematological, neurological,&#xD;
             psychiatric or other illness which compromises the ability of patients to participate&#xD;
             in the full study&#xD;
&#xD;
          7. Use of investigational drugs in the previous month or intentional use of such drugs&#xD;
             during the study&#xD;
&#xD;
          8. Intention of regular use of other medications that affect intestinal motility and / or&#xD;
             perceived&#xD;
&#xD;
          9. Lactose malabsorption is not treatable. If clinical suspicion of lactose intolerance,&#xD;
             the procedure for proper diagnosis should be made to establish or exclude a diagnosis.&#xD;
             If malabsorption is diagnosed, the patient should receive appropriate conditions of&#xD;
             treatment&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dan L. Waitzberg, phd</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of São Paulo</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Luciana Logullo</last_name>
    <phone>55-11-32846318</phone>
    <email>pesquisa@ganep.com.br</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dan Waitzberg, phd</last_name>
    <phone>55-11-72662040</phone>
    <email>pesquisa@ganep.com.br</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ganep Nutrição Humana</name>
      <address>
        <city>São Paulo</city>
        <zip>01323-001</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luciana C. Logullo</last_name>
      <phone>55-11-32846318</phone>
      <email>pesquisa@ganep.com.br</email>
    </contact>
    <investigator>
      <last_name>Dan L. Waitzberg</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Luciana C. Logullo</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maria de Lourdes T. Silva</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Juliana R. Martins</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gláucia M. Shiroma</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Amanda F. Bittencourt</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>December 2010</verification_date>
  <study_first_submitted>January 20, 2011</study_first_submitted>
  <study_first_submitted_qc>January 28, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 31, 2011</study_first_posted>
  <last_update_submitted>January 28, 2011</last_update_submitted>
  <last_update_submitted_qc>January 28, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 31, 2011</last_update_posted>
  <responsible_party>
    <name_title>SKL Functional Nutrition</name_title>
    <organization>SKL Functional Nutrition</organization>
  </responsible_party>
  <keyword>Symbiotics</keyword>
  <keyword>Fiber</keyword>
  <keyword>Constipation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Constipation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

